Eli Lilly and Co

LLY: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$921.00GlwGxbrsrcqfr

Eli Lilly's Cardiometabolic Portfolio and Pipeline Support Strong Growth and a Wide Moat

Business Strategy and Outlook

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds industry-leading growth potential as the company is launching several new blockbusters and patent losses are fading.

Sponsor Center